It’s safe to co-administer Tivicay and Prezcobix as there is no possible significant drug interaction. This combination does not mean interaction cannot exist. It’s recommended to consult with a doctor prior to starting the medication.
Tivicay has dolutegravir as an active substance. It’s an INSTI that is indicated and approved for use in combination with other antiretroviral meds for the treatment of HIV. Although it doesn’t cure the infection, it’s a highly effective anti-HIV med used without a booster to fight the virus in the patient’s body and improve the immune function, helping those infected lead longer, healthier lives [1].
Prezcobix is an antiretroviral med containing two different active ingredients: cobicistat and darunavir. It is a prescription med approved as an HIV/AIDS remedy. This drug is always used with the addition of other anti-HIV meds to fully suppress the viral load and boost the count of CD4+ cells.
Darunavir is an inhibitor of HIV-1 protease. Cobicistat is a pharmacokinetic enhancer (or a booster) which helps increase the levels of darunavir for effective treatment in the prevention of further destruction of the CD4+ cells and suppressing the viral count in the patient’s body [2].
It is safe to co-administer these two medicines. Their clinical tests show that there is no clinically significant interaction between the two drugs. Dolutegravir is not expected to affect the pharmacokinetics of darunavir/cobicistat. Prezcobix and dolutegravir can be used together without dose adjustments and are safe for HIV-1 treatment [3].
Clinically, co-administration of Tivicay and Prezcobix studied in 9 healthy volunteers shows that dolutegravir Cmax, C24, and AUC decreased by 11%, 19%, and 16%, respectively. While Darunavir Cmax, AUC, and C24 lowered by 21%, 13% and 18%, respectively and cobicistat AUC, C24h and Cmax reduced by 2%, 2%, and 14%, respectively [4].
Still, you should always consult with a healthcare professional prior to starting any treatment.